Dr. Ahmad has held prominent positions at esteemed organizations such as AstraZeneca, Dassault Systemes, and Medivir.
Dr. Rafi Ahmad
Introducing Dr. Rafi Ahmad, the visionary leader and founder of xNARA, an Indian-Norwegian scientist and Chief R&D Officer at xNARA, a personalized supplements company headquartered in Singapore with global offices.
ADVERTISEMENT
In an interview with BioTuesdays, Dr. Ahmad articulates xNARA's mission as "leveraging science and technology to deliver a convenient, customized nutritional and probiotic solution to meet individual nutritional requirements in place of multiple, generic supplements from different sources."
As per AB Newswire, Dr. Ahmad's instrumental role in advancing scientific research and innovation at xNARA has "set a precedent for the entire scientific community," showcasing his "dedication and commitment."
Exploring Dr. Ahmad's background:
He obtained his Master’s of Science in Bioinformatics from the University of Exeter before earning a Ph.D. in Bioinformatics and Computational Chemistry in Norway, establishing a robust educational foundation for his future achievements.
Dr. Ahmad has held prominent positions at esteemed organizations such as AstraZeneca, Dassault Systemes, and Medivir.
His expertise spans various domains in research & development, including Antibiotic Resistance, Bioinformatics, Big Data Analysis, Biotechnology, Drug Discovery, Genomics, and Next Generation Sequencing. Additionally, he serves as a Professor at the Inland Norway University of Applied Sciences in Hamar.
Within xNARA, Dr. Rafi Ahmad's visionary leadership drives the company's strategy, product initiatives, business ventures, and R&D endeavors. He is credited with conceptualizing, designing, and operating xNARA's factory in Hyderabad, a smart-manufacturing personalized supplements facility.
According to Chief Financial Officer Gautam Sharma, "Dr. Rafi Ahmad is the key force behind the business," illustrating his prowess as a "visionary leader" and "strategic thinker" with a deep passion for R&D and enterprise.
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
